<DOC>
	<DOCNO>NCT00003516</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally occur substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study effectiveness antineoplaston therapy treat patient stage III stage IV prostate cancer .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Stage III Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity antineoplaston A10 AS2-1 capsule patient stage III IV adenocarcinoma prostate determine proportion patient experience objective response . - Evaluate adverse effect tolerance regimen patient . OUTLINE : This open-label study . Patients receive gradually escalate dos antineoplaston A10 antineoplaston AS2-1 capsule 6 7 time day maximum tolerate dose reach . Treatment continue least 3 month absence disease progression unacceptable toxicity . Tumors measure every 4 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV adenocarcinoma prostate potentially curable surgery radiotherapy Measurable tumor tumor marker No response antiandrogen withdrawal PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL SGOT great 2 time normal No hepatic failure Renal : BUN le 60 mg/dL Creatinine great 2.5 mg/dL OR Creatinine clearance great 60 mL/min Blood ammonia normal No chronic renal failure Cardiovascular : No severe heart disease Pulmonary : No severe lung disease Other : Fertile patient must use effective contraception 4 week study participation No serious active infection fever No concurrent serious disease No prior concurrent malignancy within past 2 year PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : At least 4 week since prior hormonal therapy recover Prior corticosteroid least 2 month allow , must stable decrease dose study participation Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics At least 4 week since prior surgery recover Other : At least 4 week since prior experimental clinical trial No concurrent therapy metastatic disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>